22.29
+0.22(+1.00%)
Currency In USD
Address
7 Times Square
New York, NY 10036
United States of America
Phone
929-999-4055
Website
Sector
Healthcare
Industry
Biotechnology
Employees
53
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Mr. Marino Garcia M.B.A. | President, Chief Executive Officer & Director | 496,022 | 1966 |
| Mr. Ryan Savitz | Chief Financial Officer & Chief Business Officer | 329,651 | 1989 |
| Mr. Simrat Randhawa M.B.A., M.D. | Chief Medical Officer | 338,158 | 1970 |
| Ms. Kristina Maximenko | Chief People Officer | 0 | N/A |
| Mr. Edward G. Carr | Chief Accounting Officer | 0 | 1969 |
| Ms. Rashieda Gluck | Head of Clinical Development Operations | 0 | N/A |
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer | 0 | N/A |
| Ms. Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | 0 | N/A |
| Mr. Adam M. Veness Esq. | Senior Vice President, General Counsel & Secretary | 0 | 1986 |
| Mr. Judson Taylor | Head of Technical Operations | 0 | N/A |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.